Nano cap Can-Fite BioPharma (NYSEMKT:CANF) is up 14% premarket on robust volume on the heels of its announcement that
the FDA has provided guidance regarding the potential use of
Piclidenoson to treat COVID-19 patients. The company says the
information allows it to proceed with an IND filing for the indication.
If the FDA signs off on the IND, it will launch a
Phase 2 trial comparing Piclidenoson to standard-of-care treatment in
COVID-19 patients with moderate-to-severe symptoms.
Can-Fite is currently developing the A3AR agonist for rheumatoid arthritis and psoriasis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.